Artesunate Tolerance in Transgenic Plasmodium falciparum Parasites Overexpressing a Tryptophan-Rich Protein

ABSTRACT Due to their rapid, potent action on young and mature intraerythrocytic stages, artemisinin derivatives are central to drug combination therapies for Plasmodium falciparum malaria. However, the evidence for emerging parasite resistance/tolerance to artemisinins in southeast Asia is of great concern. A better understanding of artemisinin-related drug activity and resistance mechanisms is urgently needed. A recent transcriptome study of parasites exposed to artesunate led us to identify a series of genes with modified levels of expression in the presence of the drug. The gene presenting the largest mRNA level increase, Pf10_0026 (PArt), encoding a hypothetical protein of unknown function, was chosen for further study. Immunodetection with PArt-specific sera showed that artesunate induced a dose-dependent increase of the protein level. Bioinformatic analysis showed that PArt belongs to a Plasmodium-specific gene family characterized by the presence of a tryptophan-rich domain with a novel hidden Markov model (HMM) profile. Gene disruption could not be achieved, suggesting an essential function. Transgenic parasites overexpressing PArt protein were generated and exhibited tolerance to a spike exposure to high doses of artesunate, with increased survival and reduced growth retardation compared to that of wild-type-treated controls. These data indicate the involvement of PArt in parasite defense mechanisms against artesunate. This is the first report of genetically manipulated parasites displaying a stable and reproducible decreased susceptibility to artesunate, providing new possibilities to investigate the parasite response to artemisinins.

[1]  Xavier C Ding,et al.  Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. , 2011, Trends in parasitology.

[2]  Y. D. Sharma,et al.  Plasmodium vivax Tryptophan-Rich Antigen PvTRAg33.5 Contains Alpha Helical Structure and Multidomain Architecture , 2011, PloS one.

[3]  S. Krishna,et al.  Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. , 2010, Trends in parasitology.

[4]  M. Gatton,et al.  Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. , 2010, The Journal of infectious diseases.

[5]  W. Stein,et al.  Transporters as mediators of drug resistance in Plasmodium falciparum. , 2010, International journal for parasitology.

[6]  Lorenz von Seidlein,et al.  Artemisinin resistance: current status and scenarios for containment , 2010, Nature Reviews Microbiology.

[7]  S. Briolant,et al.  Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[8]  X. Su,et al.  Increased Tolerance to Artemisinin in Plasmodium falciparum Is Mediated by a Quiescence Mechanism , 2010, Antimicrobial Agents and Chemotherapy.

[9]  J. Peters,et al.  Role of pfmdr1 Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.

[10]  Y. Li,et al.  Artemisinin Directly Targets Malarial Mitochondria through Its Specific Mitochondrial Activation , 2010, PloS one.

[11]  Zbynek Bozdech,et al.  Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum , 2010, Nature Biotechnology.

[12]  D. Socheat,et al.  Artemisinin-resistant malaria in Asia. , 2009, The New England journal of medicine.

[13]  A. Prakash,et al.  Pharmacokinetic and Toxicological Profile of Artemisinin Compounds: An Update , 2009, Pharmacology.

[14]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[15]  Richard J Maude,et al.  The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia , 2009, Malaria Journal.

[16]  G. Posner,et al.  Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. , 2009, Biochemical pharmacology.

[17]  Zbynek Bozdech,et al.  Quantitative protein expression profiling reveals extensive post-transcriptional regulation and post-translational modifications in schizont-stage malaria parasites , 2008, Genome Biology.

[18]  S. Krishna,et al.  Artemisinins: their growing importance in medicine , 2008, Trends in pharmacological sciences.

[19]  J. Coppee,et al.  Dynamic RNA profiling in Plasmodium falciparum synchronized blood stages exposed to lethal doses of artesunate , 2008, BMC Genomics.

[20]  Ian D. Williams,et al.  Artesunate and Dihydroartemisinin (DHA): Unusual Decomposition Products Formed under Mild Conditions and Comments on the Fitness of DHA as an Antimalarial Drug , 2007, ChemMedChem.

[21]  C. Lavazec,et al.  Hypervariability within the Rifin, Stevor and Pfmc-2TM superfamilies in Plasmodium falciparum , 2006, Nucleic acids research.

[22]  J. Golenser,et al.  Current perspectives on the mechanism of action of artemisinins. , 2006, International journal for parasitology.

[23]  P. Newton,et al.  The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria , 2006, European Journal of Clinical Pharmacology.

[24]  H. Vogel,et al.  Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. , 2006, Biochimica et biophysica acta.

[25]  D. Fidock,et al.  Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. , 2006, The Journal of infectious diseases.

[26]  S. Krishna,et al.  Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance , 2006, Trends in molecular medicine.

[27]  R. Haynes.  From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. , 2006, Current topics in medicinal chemistry.

[28]  Eric Legrand,et al.  Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6 , 2005, The Lancet.

[29]  M. Wahlgren,et al.  SURFIN is a polymorphic antigen expressed on Plasmodium falciparum merozoites and infected erythrocytes , 2005, The Journal of experimental medicine.

[30]  J. Kun,et al.  Genes coding for tryptophan-rich proteins are transcribed throughout the asexual cycle of Plasmodium falciparum , 2005, Parasitology Research.

[31]  Toshihiro Horii,et al.  Developmental-stage-specific triacylglycerol biosynthesis, degradation and trafficking as lipid bodies in Plasmodium falciparum-infected erythrocytes , 2004, Journal of Cell Science.

[32]  S. Krishna,et al.  Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.

[33]  L. Dequan,et al.  Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. , 2003 .

[34]  Dennis A Dougherty,et al.  Cation-pi interactions in ligand recognition and catalysis. , 2002, Trends in pharmacological sciences.

[35]  Lorna J. Smith,et al.  Long-Range Interactions Within a Nonnative Protein , 2002, Science.

[36]  T. Wellems,et al.  Transformation of malaria parasites by the spontaneous uptake and expression of DNA from human erythrocytes. , 2001, Nucleic acids research.

[37]  T. Hunter,et al.  NeW Wrinkles for an Old Domain , 2000, Cell.

[38]  M. Hoshen,et al.  Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of ‘dormancy’, a partial cytostatic effect of the drug, and its implication for treatment regimens , 2000, Parasitology.

[39]  M. Sudol,et al.  The importance of being proline: the interaction of proline‐rich motifs in signaling proteins with their cognate domains , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  S. White,et al.  The preference of tryptophan for membrane interfaces. , 1998, Biochemistry.

[41]  T. Triglia,et al.  Stable transgene expression in Plasmodium falciparum. , 1997, Molecular and biochemical parasitology.

[42]  D. Kyle,et al.  Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. , 1996, British journal of clinical pharmacology.

[43]  D. Chakrabarti,et al.  Identification of a family of Rab G-proteins in Plasmodium falciparum and a detailed characterisation of pfrab6. , 1996, Molecular and biochemical parasitology.

[44]  T. Egan,et al.  The iron environment in heme and heme-antimalarial complexes of pharmacological interest. , 1996, Journal of inorganic biochemistry.

[45]  Timothy,et al.  Chemical Stability of Artesunate Injection and Proposal for its Administration by Intravenous Infusion , 1996, The Journal of pharmacy and pharmacology.

[46]  X. Su,et al.  Transfection of Plasmodium falciparum within human red blood cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Bork,et al.  The WW domain: a signalling site in dystrophin? , 1994, Trends in biochemical sciences.

[48]  S. Meshnick,et al.  Reaction of antimalarial endoperoxides with specific parasite proteins , 1994, Antimicrobial Agents and Chemotherapy.

[49]  O. Mercereau‐Puijalon,et al.  In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are genetically unrelated. , 1991, Molecular and biochemical parasitology.

[50]  A. Sarai,et al.  The tryptophan cluster: a hypothetical structure of the DNA-binding domain of the myb protooncogene product. , 1990, The Journal of biological chemistry.

[51]  H. Ginsburg,et al.  Characterization of permeation pathways appearing in the host membrane of Plasmodium falciparum infected red blood cells. , 1985, Molecular and biochemical parasitology.

[52]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[53]  R. Wilson,et al.  Separation of viable schizont-infected red cells of Plasmodium falciparum from human blood. , 1978, Annals of tropical medicine and parasitology.

[54]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[55]  Heng-lin Yang,et al.  Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[56]  T. Triglia,et al.  Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination. , 2002, International journal for parasitology.

[57]  Y. Wu.  Transfection of Plasmodiium falciparum within human red biood cells , 1995 .